Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease.
Ribonexus is a biotech specializing in the development of new therapies to combat cancer disease. Ribonexus, whose research and development programs are focused on the treatment of melanoma, is developing a pipeline of molecules that target the eukaryotic translation Initiation Factor-4A. (eIF4A). This target is active in a wide range of solid and hematologic cancers, including melanoma, and is linked to resistance to many current treatments. Ribonexus's goal is to deliver drugs that restore sensitivity to current targeted therapies in cancer patients who have become resistant to them.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Apr 12, 2022 | Debt Financing | €1.40M | 1 | Bpifrance | — | Detail |
Apr 12, 2022 | Grant | €600K | 1 | Bpifrance | — | Detail |
Sep 27, 2021 | Seed | €4M | 3 | AdBio partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bpifrance | Yes | Debt Financing |
AdBio partners | Yes | Seed |
Crédit Mutuel Innovation | — | Seed |
Pierre Fabre | — | Seed |